Drug intelligence / Profile preview

toripalimab + irinotecan + fluorouracil + leucovorin

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Toripalimab is a humanized IgG4 monoclonal antibody that targets the PD-1 (programmed death-1) receptor, functioning as an immune checkpoint inhibitor to restore anti-tumor T-cell activity. In the specific clinical context led by Peking University Cancer Hospital, toripalimab is being evaluated in combination with the FOLFSIM regimen for the treatment of advanced or metastatic neuroendocrine carcinoma (NEC). The FOLFSIM regimen consists of Simmtecan (a formulation of irinotecan), 5-fluorouracil (5-FU), and leucovorin (l-LV). This combination therapy aims to leverage the cytotoxic effects of chemotherapy—specifically topoisomerase I inhibition by irinotecan and thymidylate synthase inhibition by 5-FU—alongside the immune-potentiating effects of PD-1 blockade to improve outcomes in patients with high-grade neuroendocrine malignancies.

Brand names: TUOYI
Other names: FOLFSIM + toripalimabtoripalimab-Peking University-neuroendocrine carcinomaToripalimab + Simmtecan + 5-FU/LV

Targets

TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on toripalimab + irinotecan + fluorouracil + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on toripalimab + irinotecan + fluorouracil + leucovorin.

Explore the full profile